MedTrace Logo

A Study of HW243040 in Healthy Participants

NCT07737496 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2026-07-31

No results posted yet for this study

Summary

This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.

Conditions

  • Healthy

Interventions

DRUG

HW243040

HW243040 will be administered orally as a tablet.

DRUG

Placebo

Placebo will be administered orally as a tablet.

Sponsors & Collaborators

  • Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-10
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07737496 on ClinicalTrials.gov